Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX:
AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products, is pleased to announce that it will be
expanding its RHO Phyto formulary in Canada with Cannabigerol
(“CBG”) formulations into medical and adult-use channels across
Canada.
Avicanna expands its trusted RHO Phyto brand to include several
CBG formulations which will be made available across various
medical cannabis channels including Medical Cannabis by ShoppersTM
and adult use channels beginning with its two listings on the
Ontario Cannabis Store (“OCS”) in Q3 2022. As the Canadian cannabis
market continues to expand, Avicanna is leveraging its R&D
capabilities to deliver differentiated medical and wellness
products including rare cannabinoid formulations into established
commercial channels. The initial CBG formulations will include:
RHO Phyto Rapid Act THC:CBG Spray: A
combination of THC and CBG in a lemon-mint flavoured spray that
utilizes Avicanna’s sublingual delivery technology to provide fast
onset.
RHO Phyto Micro Drop THC:CBG:CBD Oil: A
combination of THC, CBG and CBD in a blood orange flavoured oil
which utilizes Avicanna’s inverted emulsion technology to provide
enhanced absorption and shelf-life stability.
RHO Phyto CBG Transdermal Relief Gel: A
combination of CBG and CBD in a fast absorbing, water-based gel.
The gel employs Avicanna’s proven deep tissue technology and
combines cannabinoids with synergistic natural ingredients and
terpenes including menthol and beta-caryophyllene.
About CBG
CBG is a rare and non-psychoactive cannabinoid which acts as the
precursor to other more commonly known cannabinoids including CBD
and THC, CBG, interacts with several receptors throughout the skin
and body that are known to be targets for inflammation, infection,
pain, as well as neurological and mood related disorders.
Specifically, modern research has investigated CBG and its
potential role in analgesia, anti-inflammation, anti-bacterial, and
for its neuroprotective properties1-5. In particular, the use of
CBG in topical formulations provides local applications for various
conditions such as arthritis, muscle aches and pain due to its
anti-inflammatory properties. Additionally, oral applications of
CBG such as the Rapid Act sublingual spray or Micro Drops oils are
expected to have systematic effects.
Avicanna’s research into CBG
Avicanna continues to research the potential therapeutic areas
of CBG with its academic and clinical partners including ongoing
studies with Thompson River University investigating the potential
anti-microbialand anti-inflammatory capabilities of CBG. The
results of these studies will provide further guidance towards
product development and clinical trials while supporting existing
commercial efforts. Moreover, the new additions to the RHO Phyto
formulary will be enrolled into Avicanna’s medical cannabis - real
world evidence trial (“MC-RWE”) conducted by the University Health
Network (UHN). This longitudinal study evaluates the efficacy of
medical cannabis on patient-reported outcomes of pain, anxiety,
sleep and depression.
Additionally, Avicanna has been conducting
research on CBG through its cultivation projects in Colombia where
the Company has developed a genetic strain of cannabis expressing
up to 17% CBG in its biomass. The proprietary genetic has also
undergone extraction and is likely the first local source of pure
CBG to be available in Colombia from where it has also been
exported to the United States and Czech Republic.
1. G Navarro, K Varani, I Reyes-Resina, VS Medina, RR
Santisteban, CSC Callado, F Vincenzi, S Casano, CF Vera, EI Canela,
PA Borea, X Nadal, R Franco (2018) Cannabigerol Action at
Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor
Complexes. Front Pharmacol 9: 632
2. Perez E, Fernandez JR, Fitzgerald C, Rouzard
K, Tamura M, Savile C. In Vitro and Clinical Evaluation of
Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid
with a Broad Range of Anti-Inflammatory and Skin Health-Boosting
Properties. Molecules. 2022; 27(2):491.
https://doi.org/10.3390/molecules27020491
3. Nachnani, R.; Raup-Konsavage, W.M.; Vrana,
K.E. The Pharmacological Case for Cannabigerol. J. Pharmacol. Exp.
Ther. 2021, 376, 204–212.
4. Schuetz, M.A., Savile, C.K., Webb, C.,
Rouzard, K., Fernández, J.R., & Pérez, E. (2021). 480
Cannabigerol: The mother of cannabinoids demonstrates a broad
spectrum of anti-inflammatory and anti-microbial properties
important for skin. Journal of Investigative Dermatology, 141.
5. Kogan NM, Lavi Y, Topping LM, Williams RO,
McCann FE, Yekhtin Z, Feldmann M, Gallily R, Mechoulam R. Novel CBG
Derivatives Can Reduce Inflammation, Pain and Obesity. Molecules.
2021; 26(18):5601. https://doi.org/10.3390/molecules26185601
About Avicanna Inc.
Avicanna is a commercial-stage international biopharmaceutical
company focused on the development, advancement, and
commercialization of evidence-based cannabinoid products for the
global consumer, medical and pharmaceutical market segments.
Leading global cannabinoid advancements, The Company actively
collaborates with renowned Canadian academic and medical
institutions in research and commercialization. Avicanna has
established an industry-leading scientific platform including
advanced R&D and clinical development that has led to the
commercialization of more than thirty products across its main
market segments:
Medical Cannabis & Wellness
Products: Marketed under the RHO Phyto™ brand these
medical and wellness products are an advanced line of
pharmaceutical-grade cannabinoid products containing varying ratios
of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The
product portfolio contains a full formulary of products including
oral, sublingual, topical, and transdermal deliveries that have
controlled dosing, enhanced absorption and stability studies
supported by pre-clinical data. The advanced formulary is marketed
with consumer, patient and medical-community education and
training.
Pharmaceutical Pipeline: Leveraging
Avicanna’s scientific platform, vertical integration, and
real-world evidence, Avicanna has created a pipeline of
patent-pending drug candidates that are indication-specific and in
various stages of clinical development and commercialization. These
cannabinoid-based drug candidates provide solutions for unmet
medical needs in the areas of dermatology, chronic pain, and
various neurological disorders. Avicanna’s first pharmaceutical
preparation (Trunerox™) is in the drug registration stage in South
America.
SOURCE Avicanna Inc.Stay Connected
For more information about Avicanna, visit www.avicanna.com,
contact Ivana Maric by email at info@avicanna.com or follow us on
social media
on LinkedIn , Twitter , Facebook or Instagram.
The Company posts updates through videos from the official
Company YouTube channel.
Cautionary Note Regarding Forward-Looking Information and
Statements
This news release contains “forward-looking information” within
the meaning of applicable securities laws. Forward-looking
information contained in this news release may be identified by the
use of words such as, “may”, “would”, “could”, “will”, “likely”,
“expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”,
“project”, “estimate”, “outlook” and other similar expressions.
Forward-looking information contained in this news release
includes, without limitation, statements related to anticipated
financial and/or operational results and outlook, including
projected revenues, projected sales growth, anticipated expansion
of product listings, the Company’s anticipated application of its
products, projected growth, anticipated geographical expansion,
receipt of authorizations and regulatory approvals, success of
clinical trials, scientific advancements and developments,
successful commercialization of products, the Company’s our
priorities, goals and strategies, industry trends and their
anticipated impact, the anticipated impact of current market
conditions on each of our segments and near term expectations,
components and supply chain constraints, and the Company’s
financial statement estimates and assumptions. Although the Company
believes that the expectations and assumptions on which such
forward looking information is based are reasonable, undue reliance
should not be placed on the forward-looking information because the
Company can give no assurance that they will prove to be correct.
Actual results and developments may differ materially from those
contemplated by these statements. Forward-looking information is
subject to a variety of risks and uncertainties that could cause
actual events or results to differ materially from those projected
in the forward-looking information. Such risks and uncertainties
include, but are not limited to current and future market
conditions, including the market price of the common shares of the
Company, and the risk factors set out in the Company’s annual
information form dated September 3, 2021 and final short form
prospectus dated November 27, 2020, filed with the Canadian
securities regulators and available under the Company’s profile on
SEDAR at www.sedar.com. The statements in this news release are
made as of the date of this release. The Company disclaims any
intent or obligation to update any forward-looking information,
whether as a result of new information, future events or results or
otherwise, other than as required by applicable securities
laws.
Avicanna (TSX:AVCN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Avicanna (TSX:AVCN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024